Isotope-dilution analysis of the effects of deoxyguanosine and deoxyadenosine on the incorporation of thymidine and deoxycytidine by hydroxyurea-treated thymus cells.
It is presumed that the dGTP and dATP needed for replicative DNA synthesis can be formed by way of either ;salvage' pathways or biosynthesis de novo. This was examined by adding hydroxyurea to cultures of rat thymus cells to inhibit ribonucleoside diphosphate reductase, a key enzyme of the ;de novo' pathway. Most of the inhibition of the incorporation of [Me-(3)H]thymidine and deoxy[5-(3)H]cytidine by low concentrations of hydroxyurea (100-500mum) was prevented by substrates of the salvage pathway (400mum-deoxyguanosine and, to a lesser extent, 200mum-deoxyadenosine). However, isotope-dilution studies indicated that the purine deoxyribonucleosides prevented inhibition by decreasing pyrimidine deoxyribonucleotide competitor pools. Evidence was obtained that a hydroxyurea-induced increase in the thymidine-competitor pool (probably dTTP) was prevented to an equal extent by deoxyguanosine and by the inhibitor of thymidylate synthase, deoxy-5-fluorouridine. These compounds had almost identical effects on hydroxyurea dose-response curves and on thymidine isotope-dilution plots. The evidence suggests that exogenous purine deoxyribonucleosides cannot prevent the inhibition by hydroxyurea of thymus-cell DNA synthesis. This could mean that, with respect to the metabolism of purine deoxyribonucleotides, ribonucleoside diphosphate reductase is tightly coupled to DNA polymerase in a multienzyme complex. The complex would not permit entry of exogenous metabolic intermediates into the ;de novo' pathway, but would still be subject to the regulatory effects of these intermediates. Thus dGTP and dATP formed from exogenous purine deoxyribonucleosides by salvage pathways might deplete pyrimidine deoxyribonucleotide competitor pools by inhibiting relatively hydroxyurea-insensitive activities of ribonucleoside diphosphate reductase.
D000818:Animals; D002478:Cells, Cultured; D003839:Deoxyadenosines / Q000494:pharmacology*; D003841:Deoxycytidine / Q000378:metabolism*; D003849:Deoxyguanosine / Q000494:pharmacology*; D006918:Hydroxyurea / Q000494:pharmacology*; D051381:Rats; D013936:Thymidine / Q000378:metabolism*; D013950:Thymus Gland / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium
D003839:Deoxyadenosines; D003841:Deoxycytidine; D014316:Tritium; D003849:Deoxyguanosine; D013936:Thymidine; D006918:Hydroxyurea